To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Nitric oxide synthase 2 mRNA expression in relation to p53 and adenomatous polyposis coli mutations in primary colorectal adenocarcinomas
Department of Biomedicine and Surgery, Division of Cell Biology, Faculty of Health Sciences, Linköping University, Linköping, Sweden.ORCID iD: 0000-0002-9826-0462
Department of Biomedicine and Surgery, Division of Cell Biology, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Department of Biomedicine and Surgery, Division of Cell Biology, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Show others and affiliations
2002 (English)In: Surgery, ISSN 0039-6060, Vol. 131, no 4, p. 384-392, article id 11935128Article in journal (Refereed) Published
Abstract [en]

Background: The inducible nitric (NO) synthase 2 (NOS2) is upregulated in breast, brain, colon, and gynecological tumors, which indicate that NO may have a role in tumorigenesis. However, little is known about the role and regulation of NOS2 in colorectal carcinomas. Recent in vitro experiments have implicated that NOS2 is downregulated by p53 accumulation. Virtual analysis of the NOS2 promoter showed putative TCF-4/Lef-1 response elements, which indicate a potential regulation of NOS2 expression by activation of the adenomatous polyposis coli (APC)/beta-catenin pathway.

Methods: NOS2 mRNA expression was investigated in 59 colorectal carcinomas by reverse transcriptase/real-time polymerase chain reaction and related to mutations in the p53, APC, and beta-catenin genes. Presence of NOS2 protein was studied by Western blot, and the localization was studied by immunohistochemistry. Loss of heterozygosity was studied in the region of the NOS2 gene.

Results: The NOS2 mRNA and protein expression were significantly higher in tumors than in control tissue. Immunohistochemistry revealed extensive NOS2 staining in the epithelial cells and, to a minor degree, in leukocytes. Increased NOS2 mRNA expression was found in Dukes' stages A and B compared with the C and D stages. No relationship was found between elevated NOS2 expression and loss of heterozygosity in the later stages according to Dukes' classification or mutations in the p53, APC, or beta-catenin genes.

Conclusions: Inactivating mutations in the p53 and APC pathways are not the main explanation for the increased NOS2 expression found in colorectal tumors.

Place, publisher, year, edition, pages
Elsevier, 2002. Vol. 131, no 4, p. 384-392, article id 11935128
National Category
Cancer and Oncology Cell and Molecular Biology
Identifiers
URN: urn:nbn:se:oru:diva-87258DOI: 10.1067/msy.2002.121888ISI: 000175064200005PubMedID: 11935128Scopus ID: 2-s2.0-0036213587OAI: oai:DiVA.org:oru-87258DiVA, id: diva2:1499202
Available from: 2020-11-07 Created: 2020-11-07 Last updated: 2023-12-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Fransén, KarinSirsjö, Allan

Search in DiVA

By author/editor
Fransén, KarinSirsjö, Allan
Cancer and OncologyCell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 139 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf